Indicated for the management of breakthrough pain in cancer patients 18 years of age or older who are already receiving and who are tolerant to opiate therapy for their underlying persistent cancer pain.
Micronized sublingual formula provides faster absorption and greater bioavailability than oral opioids.
Provides greater transmucosal absorption and greater bioavailability than oral transmucosal fentanyl citrate.
Has a short half life to relieve breakthrough pain with no long-lasting narcotic effect.
Adverse events: includes nausea, constipation, somnolence and headache.
Initiation of therapy is with 100 µg tablets.
If adequate pain relief is not achieved after 30 minutes a second hundred micrograms dose can be administered.